Cargando…
Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry
BACKGROUND: Basiliximab (BSX) and antithymocyte globulins (ATGs), are two major immunosuppressive agents commonly used as induction therapy for kidney transplant (KT) recipients. The superiority of ATG over BSX has not been well established, especially in elderly KT recipients with low immunological...
Autores principales: | Lee, Jun Young, Kim, Sung Hwa, Park, Yeon Ho, Park, Jae Berm, Lee, Su Hyung, Yang, Jaeseok, Kim, Myoung Soo, Kim, Deok Gie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Nephrology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576457/ https://www.ncbi.nlm.nih.gov/pubmed/35977904 http://dx.doi.org/10.23876/j.krcp.21.310 |
Ejemplares similares
-
The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study
por: Hong, Su Yeon, et al.
Publicado: (2023) -
Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin
por: Jeong, Rachel, et al.
Publicado: (2020) -
Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study
por: Lam, Ngan N., et al.
Publicado: (2021) -
Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
por: Kim, Sang Jin, et al.
Publicado: (2020) -
Antithymocyte Globulin: Indiscriminate Use and Complications
por: Khan, Taqi, et al.
Publicado: (2019)